Squibb Company (NYSE:BMY) today announced that the U.S. Food and
Drug Administration (FDA) has accepted for filing and review the
supplemental Biologics License Application (sBLA) for Yervoy for
the adjuvant treatment of patients with stage 3 melanoma who are at high
risk of recurrence following complete surgical resection.
for U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Yervoy® (ipilimumab) as Adjuvant Treatment for Patients with Stage 3 Melanoma Who Are at High Risk of Recurrence investment picks